Shu Dong Md

6PUBLICATIONS
7CO-AUTHORS
Predictive and prognostic markersSolid tumoursTraditional Chinese medicine and treatments
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Aug 11, 2026
Biomarker-Stratified Phase II Trial of Trastuzumab Rezetecan in Advanced Salivary Gland Carcinoma Across Cohorts With High and Low Human Epidermal Growth Factor Receptor 2 Expression.

|Mar 12, 2026
Global research trends and foci of ablation therapies for liver tumours: a scientometric study.

Shu Dong, Chien-Shan Cheng, Lin Xie

|Nov 07, 2024
Insights on Chinese and European consensus for USgHIFU treatment of pancreatic cancer.

Zhiqiang Meng, Shu Dong

|Oct 16, 2024
"Huanglianjiedu Decoction" Against Pancreatic Adenocarcinoma Proliferation of by Downregulating the PI3K/AKT/mTOR and MAPK/ERK1/2 Signaling Pathways.

Shu Dong Md, Panling Xu Md, Peiwen Yang Md

|Nov 09, 2023
Sequential high-intensity focused ultrasound treatment combined with chemotherapy for inoperable pancreatic cancer: a retrospective analysis for prognostic factors and survival outcomes.

Shu Dong, Ailing Zhong, Huili Zhu

|Aug 03, 2019
Identification of Prognostic Biomarkers and Drugs Targeting Them in Colon Adenocarcinoma: A Bioinformatic Analysis.

Shu Dong, Zhimin Ding, Hao Zhang

Pageof 1

Frequent Collaborators

1 joint publications

Zhiqiang Meng

1 joint publications

Guang-Liang Chen

1 joint publications

Xin Liu

1 joint publications

Xiao Shi